463 related articles for article (PubMed ID: 33236534)
1. TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy.
Xu D; Li S; Wang L; Jiang J; Zhao L; Huang X; Sun Z; Li C; Sun L; Li X; Jiang Z; Zhang L
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):192-208. PubMed ID: 33236534
[TBL] [Abstract][Full Text] [Related]
2. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.
Xu D; Zhao L; Jiang J; Li S; Sun Z; Huang X; Li C; Wang T; Sun L; Li X; Jiang Z; Zhang L
J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1306-1320. PubMed ID: 32869445
[TBL] [Abstract][Full Text] [Related]
3. p-TAK1 acts as a switch between myoblast proliferation phase and differentiation phase in mdx mice via regulating HO-1 expression.
Fan S; Huang X; Tong H; Hong H; Lai Z; Hu W; Liu X; Zhang L; Jiang Z; Yu Q
Eur J Pharmacol; 2022 Oct; 933():175277. PubMed ID: 36113553
[TBL] [Abstract][Full Text] [Related]
4. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
[TBL] [Abstract][Full Text] [Related]
5. Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice.
Freeman E; Langlois S; Leyba MF; Ammar T; Léger Z; McMillan HJ; Renaud JM; Jasmin BJ; Cowan KN
Skelet Muscle; 2024 Apr; 14(1):8. PubMed ID: 38671506
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
7. Hemojuvelin is a novel suppressor for Duchenne muscular dystrophy and age-related muscle wasting.
Zhang P; He J; Wang F; Gong J; Wang L; Wu Q; Li W; Liu H; Wang J; Zhang K; Li M; Huang X; Pu C; Li Y; Jiang F; Wang F; Min J; Chen X
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):557-573. PubMed ID: 30884219
[TBL] [Abstract][Full Text] [Related]
8. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
9. Lipin1 plays complementary roles in myofibre stability and regeneration in dystrophic muscles.
Jama A; Alshudukhi AA; Burke S; Dong L; Kamau JK; Voss AA; Ren H
J Physiol; 2023 Mar; 601(5):961-978. PubMed ID: 36715084
[TBL] [Abstract][Full Text] [Related]
10. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
[TBL] [Abstract][Full Text] [Related]
11. Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts.
Gosselin MRF; Mournetas V; Borczyk M; Verma S; Occhipinti A; Róg J; Bozycki L; Korostynski M; Robson SC; Angione C; Pinset C; Gorecki DC
Elife; 2022 Sep; 11():. PubMed ID: 36164827
[TBL] [Abstract][Full Text] [Related]
12. Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model.
Roy A; Koike TE; Joshi AS; Tomaz da Silva M; Mathukumalli K; Wu M; Kumar A
JCI Insight; 2023 May; 8(10):. PubMed ID: 37071470
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
14. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
[TBL] [Abstract][Full Text] [Related]
15. Sertoli Cells Improve Myogenic Differentiation, Reduce Fibrogenic Markers, and Induce Utrophin Expression in Human DMD Myoblasts.
Salvadori L; Chiappalupi S; Arato I; Mancuso F; Calvitti M; Marchetti MC; Riuzzi F; Calafiore R; Luca G; Sorci G
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680138
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.
Kumar A; Bhatnagar S; Kumar A
Am J Pathol; 2010 Jul; 177(1):248-60. PubMed ID: 20472898
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
18. Pluripotent stem cell-induced skeletal muscle progenitor cells with givinostat promote myoangiogenesis and restore dystrophin in injured Duchenne dystrophic muscle.
Xuan W; Khan M; Ashraf M
Stem Cell Res Ther; 2021 Feb; 12(1):131. PubMed ID: 33579366
[TBL] [Abstract][Full Text] [Related]
19. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
[TBL] [Abstract][Full Text] [Related]
20. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.
Bostick B; Shin JH; Yue Y; Wasala NB; Lai Y; Duan D
J Mol Cell Cardiol; 2012 Aug; 53(2):217-22. PubMed ID: 22587991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
